![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
AvenCell
Company Type: Therapeutics
Main focus: Development of autologous CAR-T cell therapies
Company stage: Pre-clinical
Diseases: Neurodegenerative disorders
Genome-editing tool: CRISPR-Cas
Funding stage: Series A
Location: Dresden, Germany
Website: https://avencell.com/
Pipeline: https://avencell.com/pipeline/
Partners:
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_avencell_2fed11ccaa_516436d506.png)
AvenCell brings together switchable universal T-cell technology developed by the former Cellex subsidiary GEMoaB GmbH, with a license to Intellia Therapeutics proprietary CRISPR-Cas9-based allogeneic platform to create a pipeline of autologous and allogeneic universal reprogrammable T cell products, focused initially on hard-to-treat cancers.